FDA Calls for Testing Before Treatment With Widely Used Chemotherapies

FDA Calls for Testing Before Treatment With Widely Used Chemotherapies

(MedPage Today) -- Oncology specialists should inform patients about a risk of serious toxicity related to dihydropyrimidine dehydrogenase (DPD) deficiency and should test for DPYD variants before starting treatment with capecitabine (Xeloda) and...

Updated Capecitabine/5-FU Labeling Calls for DYPD Testing Before Use

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk severe or fatal toxicities.